BRIEF-Astrazeneca Says Tremelimumab Accepted Under Priority Review In U.S.

AstraZeneca PLC:

* ASTRAZENECA PLC - TREMELIMUMAB US PRIORITY REVIEW FOR IMFINZI COMBO

* ASTRAZENECA - TREMELIMUMAB ACCEPTED UNDER PRIORITY REVIEW IN US FOR PATIENTS WITH UNRESECTABLE LIVER CANCER IN COMBINATION WITH IMFINZI Source text for Eikon: Further company coverage:

(This story has not been edited by Devdiscourse staff and is auto-generated from a syndicated feed.)